Description
Mounjaro (tirzepatide) 2.5 mg KwikPen
Mounjaro contains tirzepatide, a prescription medicine used for glycaemic control in type 2 diabetes mellitus. The 2.5 mg strength is the starting dose form and is not intended for glycaemic control by itself. Tirzepatide is a dual incretin receptor agonist that acts on GIP and GLP-1 pathways.
Active Ingredient and Medicine Class
Active ingredient: tirzepatide.
Medicine class: dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
This class of medicine is used to improve blood glucose control in people with type 2 diabetes.
Established Medical Uses
Mounjaro is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. U.S. prescribing information also states an indication in pediatric patients 10 years of age and older for this use. Its approved use is for diabetes management, not as a general weight-loss medicine.
How It Works
Tirzepatide activates GIP and GLP-1 receptors. These hormones help regulate insulin release after meals, reduce glucagon secretion when glucose is elevated, and slow gastric emptying. Together, these effects can improve blood sugar control.
Important Safety Information
Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2, and in people with serious hypersensitivity to tirzepatide or any excipient.
Important precautions include the risk of pancreatitis, hypoglycaemia when used with insulin or insulin secretagogues, acute kidney injury related to dehydration, severe gastrointestinal reactions, gallbladder disease, and possible worsening of diabetic retinopathy in patients with a history of eye disease. It may also delay absorption of oral medicines because it slows gastric emptying.
Serious allergic reactions, including anaphylaxis and angioedema, have been reported.
Possible Side Effects
The most commonly reported adverse effects include nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain. Less common but clinically important reactions can include severe gastrointestinal intolerance, low blood sugar with certain diabetes medicines, pancreatitis, gallbladder problems, dehydration-related kidney injury and hypersensitivity reactions.
Scientific Evidence
Clinical trials and reviews in PubMed show that tirzepatide improves HbA1c and often reduces body weight in adults with type 2 diabetes. Comparative trials have also found greater glucose-lowering and weight reduction than some other injectable diabetes medicines in studied populations. Safety findings across trials are consistent with gastrointestinal adverse effects being the most frequent treatment-limiting events.
Medical Information Notice
This summary is for educational purposes only and is based on sources available at the time of review. It does not replace the official patient leaflet, prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- FDA: MOUNJARO (tirzepatide) Injection, for subcutaneous use — Prescribing Information
- DailyMed: MOUNJARO / MOUNJARO KWIKPEN — Full Prescribing Information
- Dashora et al.: Tirzepatide: A Review in Type 2 Diabetes — Drug, 2024
